Thyroid cancer complicating familial adenomatous polyposis: mutation spectrum of at-risk individuals by unknown
Septer et al. Hereditary Cancer in Clinical Practice 2013, 11:13
http://www.hccpjournal.com/content/11/1/13RESEARCH Open AccessThyroid cancer complicating familial
adenomatous polyposis: mutation spectrum of
at-risk individuals
Seth Septer1*, Voytek Slowik2, Ryan Morgan4, Hongying Dai3 and Thomas Attard1Abstract
Background: Lifetime risk of thyroid cancer associated with FAP has been reported as 1-2%. The mean age at
diagnosis of thyroid carcinoma in FAP has been reported at 28 years. The aims of this paper are to better
understand gene mutations associated with thyroid cancer and refine surveillance recommendations for patients
with FAP.
Methods: We performed a search in Pubmed, Ovid Medline and Embase with the terms ("Thyroid Gland"[Mesh] OR
"Thyroid Neoplasms"[Mesh]) AND "Adenomatous Polyposis Coli"[Meshdenomatous Polyposis Coli"[Mesh] to identify
subjects with thyroid cancer and FAP. As a reference group for APC mutations in the unselected FAP population,
we used the UMD-APC database referenced in the Orphanet portal, which includes APC mutation data on 2040
individuals with FAP.
Results: There were 115 reported cases of thyroid cancer in patients with FAP (95 female: 11 male) with an average
age of 29.2 years. Gene mutation testing results were reported in 48 patients. On comparing the prevalence of APC
mutation in the population of FAP patients with thyroid cancer and the prevalence of the same mutation in the
reference population an increased odds ratio was evident in individuals harboring an APC mutation at codon 1061
(OR: CI 4.1: 1.7-8.9). Analysis of the prevalence of thyroid cancer in individuals with FAP segregated by the region of
the gene affected shows an increased risk of thyroid cancer in individuals harboring mutations proximal to codon
512 (OR 2.6, p 0.0099).
Conclusions: There is increased risk for thyroid cancer in individuals with APC mutations at the 5' end (proximal to
codon 528) along with the established high risk group harboring mutation at codon 1061. It is suggested that
these patients might benefit from directed surveillance by annual ultrasound from age 18 years onwards.
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Papillary thyroid carcinomaIntroduction
Familial Adenomatous Polyposis (FAP) is an autosomal
dominant syndrome with a predisposition for colorectal
cancer. FAP is characterized by profuse adenomatous
polyposis in the colon and rectum with nearly 100% life-
time risk of colorectal cancer. Approximately 1% of all
cases of colorectal cancer each year in the United States
are due to FAP [1]. Without prophylactic colectomy, the* Correspondence: ssepter@cmh.edu
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reproduction in any medium, provided the ormean age of colorectal cancer is 39 years and the mean
life expectancy is 42 years [2]. Colorectal involvement in
the classic form of FAP typically presents in childhood
or early adolescence whereas a milder pattern of colo-
rectal involvement (Attenuated FAP) may present later
in life with a later age at presentation of colon cancer.
Most patients with FAP harbor a germline mutation in
the adenomatous polyposis coli (APC) gene on chromo-
some 5q21. The majority of APC mutations are either
frameshift or nonsense mutations resulting in a truncated
protein [3]. Penetrance is nearly complete for the colonic
phenotype but is variable for extra-colonic manifestationsLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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protein consisting of 2843 amino acids. More than 60% of
APC mutations are found in the mutation cluster region
(MCR) between codons 1284 and 1580 [4], or 1284–1464
[5]. The two most frequently described germline muta-
tions are located at codon 1309 (c3927_3931delAAAGA)
and codon 1061 (c.3183_87delACAAA) [6] Disease ex-
pression in FAP is to some extent dependent on the
specific APC mutations (genotype-phenotype correl-
ation; Figure 1).
Extra-intestinal manifestations are common in FAP;
children are also at risk and thus need to be assessed
regularly from birth. Extra-colonic manifestations in chil-
dren with FAP may include a 750–7500 fold increased risk
of hepatoblastoma [7,8] as well as an increased risk of
medulloblastoma [9], osteomas, supernumerary teeth
or missing teeth, congenital hypertrophy of retinal pig-
ment epithelium (CHRPE), desmoid tumors and fibromas.
Several referral centers have adopted an extra-intestinal
tumor surveillance strategy that includes reported
genotype-phenotype correlations [10,11].
Thyroid cancer in a patient with FAP was first de-
scribed by Crail in 1949 [12]. In this group, lifetime risk
of thyroid cancer has been reported as 1-2% [13-17].
This may be even higher in certain kindreds as Herraiz
et al. reported thyroid carcinoma in 12% of 51 patients
with FAP [18]. Thyroid cancer observed in FAP is typic-
ally the cribiform-morular variant of papillary thyroid
carcinoma (PTC) [19]. The mean age at diagnosis of thy-
roid carcinoma in FAP has been reported at 25–28 years
[16,20] with one third concomitant diagnosis, one third
first diagnosis of FAP and one third diagnosed first with
thyroid cancer [16,20].
While the female:male ratio in sporadic cases of PTC is
3–4:1, the magnitude of the disparity appears to be even
higher in PTC associated with FAP. In such patients, the
female predominance is reported to be 10–17:1 [6,21]. Ac-
cordingly, female patients with FAP have been estimatedFigure 1 Diagram of APC gene showing genotype-phenotype correla
Groen et al. [21]. With kind permission from Springer Science and Businesto have a 100 to 160 fold risk of thyroid cancer compared
to normal individuals [14,22] with peak incidence less
than 30 years of age. Although an increased risk is recog-
nized, clinical surveillance guidelines for PTC in FAP pa-
tient’s remains poorly defined. Most centers advise annual
clinical examination with consideration for ultrasound.
Guidelines from a previous paper [21] suggest looking for
palpable nodules at least yearly and referral to an endo-
crinologist for fine needle aspiration (FNA) if nodules are
present [23]. Several authors have recommended liberal
use of thyroid ultrasound in FAP patients [18,24]. Others
have recommended FNA for thyroid nodules greater than
1 cm in size [25,26].
Phenotype-genotype correlation of the development of
thyroid cancer in FAP has been attempted before but
the observations remain conflicting. Previous literature
has stated that papillary thyroid carcinoma is more
prevalent in codons 140–1309 (Figure 1). Thirteen of fif-
teen patients with thyroid carcinoma and FAP had mu-
tations in the APC gene between codons 778 and 1309
in a study by Cetta [27]. Another study [15] screened 16
patients with both FAP and PTC. Germline APC gene
mutations were noted in 12 of 13 patients tested; in nine
of them the mutation was located before codon 1286,
and outside the mutation cluster region (MCR). Harb
and coworkers [28] also reiterated the majority of APC
mutations associated with PTC appear to be proximal to
the MCR, although there appears to be significant over-
lap with the APC gene region (codons 463–1387) associ-
ated with congenital hypertrophy of the retinal pigment
epithelium (CHRPE) [21,29,30].
This study is a systematic review of the genotype-
phenotype associations of thyroid cancer in patients with
FAP. Literature search was undertaken to find all cases
of thyroid malignancy that had a described mutation in
the APC gene. This was further refined by controlling
for the frequency distribution of mutations in a refer-
ence database of APC gene mutations in FAP patients.tions of extra-intestinal manifestations of FAP as depicted by
s Media.
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ated with thyroid cancer and to better use specific APC
gene mutations to refine surveillance recommendations.
Methods
We performed a search in Pubmed, Ovid Medline and
Embase with the terms ("Thyroid Gland"[Mesh] OR
"Thyroid Neoplasms"[Mesh]) AND "Adenomatous Polyp-
osis Coli"[Mesh] NOT "Comment"[Publication Type] OR
"Letter"[Publication Type] OR "Editorial"[publication
type]). The reference lists of the retrieved articles were
also reviewed to identify additional studies, as were review
articles on the subject.
The peer reviewed articles identified through the initial
search were reviewed and the authors independently ab-
stracted information from each of these studies. Each
study was reviewed for sample size, diagnosis of FAP,
diagnosis of TC and documentation of APC mutation.
Studies with incomplete or duplicate patient reports
were excluded. The remaining patients with information
relating to gender, age at onset of thyroid cancer or dur-
ing illness and specific mutations of APC gene were ac-
crued to a database for further evaluation.
As a reference group for APC mutations in the unse-
lected FAP population, we used the UMD-APC database
referenced in the Orphanet portal (http://www.umd.be/
APC/). This includes data on 2040 individuals with FAP
including their APC gene mutation.
Fisher’s exact test was performed to compare the muta-
tion rate between reference and thyroid cancer patients
with mutation. Odds ratio and 95% exact confidence inter-
val were determined. The 95% confidence interval of sig-
nificant odds ratio does not cross 1. Statistical significance
was claimed with p < 0.05. All statistical analyses were
performed in SAS 9.2 (Cary NC).
Results
The initial search resulted in 49 articles related to thy-
roid cancer and FAP. After review, 18 studies were de-
termined as meeting inclusion criteria. These eighteen
studies included a total of one hundred fifteen reported
cases of thyroid cancer in patients with FAP. Affected
individuals were mainly female (96 F: 11 M) with an
average age of 29.2 (+/− 10.3) years.
APC gene mutation testing was reported in 48 patients
(Table 1). The reference population of individuals with
FAP included 2040 individuals. We compared the preva-
lence of APC mutations in the published patients with
thyroid cancer to the prevalence of the same mutation
in the reference population (see Table 1). An increased
odds ratio for thyroid cancer was evident for mutations
at codon 1061 (OR: CI 4.1: 1.7-8.9). Mutations at codon
1309 conferred less risk (0.8: 0.2-2.0). Without adjusting
for the reference population prevalence, individuals withmutations at codon 1061 (18.7%) and 1309 (10.42%)
were most frequently identified with thyroid cancer. How-
ever, these two mutations were also the most common
APC mutations in the reference population accounting for
5.3% and 12.9% of cases respectively. Using this compari-
son mutations in codon 1309 were actually less common
as a percentage of the total in the FAP-TC group than in
the FAP reference group.
Further analysis of the prevalence of thyroid cancer in
individuals with FAP segregated by the region of the
gene affected shows an increased risk of thyroid cancer
in individuals harboring mutations proximal to codon
512 (OR 2.6, p 0.0099). An intermediate risk was found
for individuals harboring mutation in codons 513 through
937 (OR 1.6, p NS) and the lowest risk is in individuals
with mutation distal to codon 938 (OR 0.4, p 0.0033) even
when including all cases with the high risk codon 1061
(Table 1).
Discussion
To our knowledge this is the largest group of pooled
cases of thyroid cancer in patients with FAP including
APC mutation data reported to date. This study corrob-
orates earlier observations that thyroid cancers in pa-
tients with FAP are more prevalent in younger females.
The mean age at onset (29.2 years) was similar to that
previously reported. This is, however, the first analysis
that attempts to define the actual risk of thyroid cancer
associated with specific APC mutations in FAP patients
whilst adjusting for the frequency distribution of APC
mutations in FAP patients.
Our observations expand on work previously reported
by Cetta et al. [20] which compared the difference in in-
cidence of germline mutations before and after codon
1220 between 317 FAP patients without PTC and 24 pa-
tients with FAP and PTC. They reported a significant
difference (p = 0.005), with FAP and PTC more common
in those with mutations proximal to codon 1220. The
authors then suggested that mutations at 5’ end of exon
15 may direct PTC screening in patients with FAP.
Using the same arbitrary cutoff, the same difference was
found in our group, which comprised a larger reference
and FAP-PTC group (p = 0.0001).
This study shows that there is an increased risk of thy-
roid cancer associated with APC mutation in codon
1061; this is true both in absolute numbers of patients
reported as well as when adjusted to the frequency of
APC mutations at this locus in an unselected population.
This observation is in line with prior observations al-
though our analysis suggests that the degree of risk con-
ferred is modest in comparison with other, less common
mutations. In fact, although 24% of reported cases of
thyroid cancer in FAP harbored a mutation proximal to
codon 513, this range of mutations accounts for only
Table 1 Comparison of APC mutation frequency in reference population of individuals with FAP, with APC mutation
frequency in reported cases of thyroid cancer in individuals with FAP – including comparison of regional mutation
frequency
Codon Mutation frequency in RP TC cases TC frequency of mutation Odds ratio (CI) by region OR (CI) p-value
140 0.05% 1 2.08% 2.6 (1.2-5.1) p = 0.0099 43.4 (0.5-3410.0) 0.0454
157 0.15% 1 2.08% 14.5 (0.3-183) NS
159 0.05% 1 2.08% 43.4 (0.5-3410.0) 0.0454
175 0.05% 1 2.08% 43.4 (0.5-3410.0) 0.0454
180 0% 1 2.08% ∞ (2.2-∞) 0.0230
278 0.39% 2 4.17% 11.1(1.1-57.3) 0.0207
302 0.64% 1 2.08% 3.3 (0.1-23.0) NS
312 0% 2 4.17% ∞ (12.4-∞) 0.0005
499 0.34% 1 2.08% 6.2 (0.1-49.6) NS
512 0% 1 2.08% ∞ (2.2-∞) 0.0230
528 0.05% 2 4.17% 1.6 (0.7-3.4) p = 0.1906 88.7 (4.5-5237.0) 0.0015
564 0.69% 2 4.17% 6.3 (0.7-28.6) NS
593 0.25% 1 2.08% 8.7 (0.2 - 79.4) NS
698 0.05% 3 6.25% 136.1 (10.5-7145.1) 0.00004
778 0.15% 1 2.08% 14.5 (0.3-183) NS
938 0.10% 1 2.08% 0.4 (0.2-0.8) p = 0.0033 21.7 (0.4-420.8) NS
976 0.05% 1 2.08% 43.4 (0.5-3410.0) 0.0454
993 0.10% 1 2.08% 21.7 (0.4-420.8) NS
1061 5.34% 9 18.75% 4.1 (1.7-8.9) 0.0011
1068 0.83% 2 4.17% 5.2 (0.6-22.8) NS
1105 0.10% 1 2.08% 21.7 (0.4-420.8) NS
1110 0.25% 1 2.08% 8.7 (0.2 - 79.4) NS
1275 0% 1 2.08% ∞ (2.2-∞) 0.0230
1309 12.89% 5 10.42% 0.8 (0.2-2.0) NS
1464 0.59% 1 2.08% 3.6 (0.1-25.2) NS
1948 0% 2 4.17% ∞ (12.4-∞) 0.0005
2092 0% 2 4.17% ∞ (12.4-∞) 0.0005
48
RP = reference population (from UMD/APC database).
TC = thyroid cancer.
NS = not significant.
CI = confidence interval.
Bold= statistically significant odds ratio by region, or bold to highlight the most common APC mutations.
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database. Conversely, 82.4% of FAP patients from this
database were reported with mutation at the 3’ end; dis-
tal to codon 938, but only 56.2% of the reported cases of
thyroid cancer localized to the same region, paradoxic-
ally suggesting that individuals harboring mutations
within that spectrum are relatively low risk although in
absolute terms of occurrence they are reported more
often. This observation also raises consideration for
the need to re-examiner some other recommendations
on phenotype-genotype correlations that are of even
greater clinical relevance. These include the mutation
spectrums associated with desmoids, hepatoblastoma,medulloblastoma and upper gastrointestinal involve-
ment in individuals with FAP.
Genotype-directed disease surveillance has repeatedly
been proposed as a potential strategy geared toward the
detection of early intestinal and extra-colonic malig-
nancy in FAP. The increased relative risk for TC in
young, female patients with FAP has been previously
noted and is corroborated in our data. Whether the spe-
cific APC mutation prompts different PTC surveillance
techniques and schedules in certain groups of patients
has not been previously determined.
Previous authors have recommended surveillance in-
cluding yearly thyroid exams [14,31] or ultrasound [18,32]
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palpable thyroid nodules are appreciated in 5% of women
and 1% of men in the general population [33,34], while
the prevalence of thyroid nodules detected by high-
resolution ultrasound is 19-67% in randomly selected indi-
viduals [35]. Thus, it appears a portion of nodules will not
be appreciated by physical exam only. Ultrasound examin-
ation is clearly superior to physical examination alone
[36], and if we can extrapolate from epidemiologic obser-
vations in the general population earlier detection of le-
sions will translate in better patient outcomes [37].
Although proof of improved outcomes from targeted,
more intensive surveillance in this specific population is
lacking, our observations support annual ultrasound
examination in female patients, 18 years of age and older
with FAP harboring mutation at codon 1061, or any muta-
tion proximal to codon 528, followed by fine needle aspir-
ation when indicated. Continued annual palpation of the
neck as is established standard of care for clinical surveil-
lance for thyroid masses should be continued in all other
patients, with a low threshold for subsequent ultrasound.
The more intensive surveillance for thyroid involvement
in this population seems justified in view of the younger
age at diagnosis and more aggressive behavior reported in
syndromic compared with sporadic thyroid cancer includ-
ing higher rates of reoperation and death in the syndromic
cases [38].
This study has several limitations; it is a pooled met-
analysis of a group of publications ranging from registry
based reports, case series and case reports. Thyroid ma-
lignancy in FAP was not the focus of most of the in-
cluded studies. Although efforts were made to exclude
duplicate studies through careful scrutiny of publications
from the same author, group or center we cannot be
sure that individual patients were not included in more
than one registry or seen at more than one center
resulting in over-representation in the final dataset. This
appears to have been unlikely given that duplicate –
identical clinical data could not be found in the final
dataset. The study also necessarily suffers from the in-
clusion of studies over a period of time during which
testing modalities for APC mutations has changed with
test results (egs. segmental involvement of APC with
codon involvement through sequencing) and results in
attrition of the data that may not be comparable. It is
noteworthy that our search revealed only 48 published
patients with FAP, a specified APC gene mutation and
thyroid cancer. This underscores the need for a common
resource for the pooling of mutation analysis and clinical
features of this and other relatively rare polyposis syn-
dromes through expanded use of registries.
In conclusion, our study reiterates the importance of
continued clinical vigilance for thyroid cancer in youn-
ger women with FAP. Building upon earlier studieshowever, we emphasize the increased risk in individuals
with mutations at the 5’ end (proximal to codon 528)
along with the established high risk group harboring
mutation at codon 1061. It is suggested that these pa-
tients might benefit from directed surveillance by annual
ultrasound from age 18 years onwards.
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